On Monday, Janux Therapeutics Inc (NASDAQ: JANX) opened lower -7.22% from the last session, before settling in for the closing price of $29.10. Price fluctuations for JANX have ranged from $28.91 to $71.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 32.33%. Company’s average yearly earnings per share was noted -41.25% at the time writing. With a float of $49.57 million, this company’s outstanding shares have now reached $59.06 million.
Let’s determine the extent of company efficiency that accounts for 81 employees. In terms of profitability, gross margin is 90.2%, operating margin of -933.58%, and the pretax margin is -651.62%.
Janux Therapeutics Inc (JANX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Janux Therapeutics Inc is 16.13%, while institutional ownership is 107.90%. The most recent insider transaction that took place on Mar 06 ’25, was worth 11,453,023. In this transaction Director of this company bought 372,093 shares at a rate of $30.78, taking the stock ownership to the 10,031,081 shares. Before that another transaction happened on Mar 05 ’25, when Company’s Director bought 341,742 for $30.64, making the entire transaction worth $10,471,352. This insider now owns 9,658,988 shares in total.
Janux Therapeutics Inc (JANX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -41.25% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Check out the current performance indicators for Janux Therapeutics Inc (JANX). In the past quarter, the stock posted a quick ratio of 59.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 150.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.28, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -2.32 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Looking closely at Janux Therapeutics Inc (NASDAQ: JANX), its last 5-days average volume was 0.68 million, which is a drop from its year-to-date volume of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 12.55%. Additionally, its Average True Range was 1.83.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 1.34%, which indicates a significant decrease from 10.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.74% in the past 14 days, which was lower than the 90.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.41, while its 200-day Moving Average is $44.63. However, in the short run, Janux Therapeutics Inc’s stock first resistance to watch stands at $27.95. Second resistance stands at $28.91. The third major resistance level sits at $29.69. If the price goes on to break the first support level at $26.22, it is likely to go to the next support level at $25.44. Now, if the price goes above the second support level, the third support stands at $24.49.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
There are currently 59,105K shares outstanding in the company with a market cap of 1.60 billion. Presently, the company’s annual sales total 10,590 K according to its annual income of -68,990 K. Last quarter, the company’s sales amounted to 440 K and its income totaled -28,060 K.
